We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

DIASOURCE

Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases read more Featured Products: More products

Download Mobile App




DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products

By LabMedica International staff writers
Posted on 31 Jul 2018
DIAsource Immunoassays (Brabant Wallon, Belgium), a BioVendor group company, has entered into a strategic agreement with ZenTech (Angleur, Belgium) under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.

DIAsource ImmunoAssays is a diagnostics company specialized in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. More...
It delivers manual RIA and ELISA kits and open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. ZenTech specializes in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening. It has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity.

Both the companies have long standing collaborations for more than 15 years, with DIAsource already successfully managing a part of the commercialization of the ZenTech portfolio. The current transfer of RIA products from ZenTech to DIAsource is in line with their strategies. The portfolio to be transferred includes the complete line of special RIAs with thyroid markers and markers for fertility and salt balance. Effective July 24, 2018, DIAsource Immunoassays has assumed commercial ownership of ZenTech’s RIA product portfolio and will service clients from order to shipment, while ZenTech will remain the manufacturer during the transition period in which the production will be transferred to DIAsource. The transfer of production will be done in close collaboration and in phases to be concluded by September 30, 2019.

“Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases,” said Jean-Claude Havaux, Chairman of the Board, ZenTech. “Today's acquisition of the RIA products by ZenTech’s commercial partner DIAsource will guarantee RIA customers are offered long-term service and excellence in logistics worldwide. This transaction will give ZenTech the opportunity to focus on new innovative product lines and other technologies such as molecular diagnostics and mass spectrometry.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide,” said Jef Vangenechten, CEO of DIAsource Immunoassays. “We experience that RIA remains important as the gold standard for assays that are not available on automated systems or for parameters that require a higher analytical accuracy, whereby manual assays offer benefits in terms of quality and flexibility versus price. DIAsource now has a unique position by combining the most complete offering of RIA specialty assays on the market with the ability to offer various RIA automation solutions. Furthermore our manual assays also allow customization for life science research and screening,” added Vangenechten.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.